PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS-Reference-Cited by-同舟云学术

PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS

Published:2021-02-12 Issue:4 Volume:60 Page:531-538
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Abdulla Maysaa¹,Alexsson Andrei²,Sundström Christer¹,Ladenvall Claes²,Mansouri Larry³,Lindskog Cecilia⁴,Berglund Mattias⁵,Cavelier Lucia²,Enblad Gunilla⁵^ORCID,Hollander Peter¹,Amini Rose-Marie¹^ORCID

Affiliation:

1. Clinical and Experimental Pathology, Department of Immunology, Genetics and Pathology, Uppsala University and University Hospital, Uppsala, Sweden

2. Clinical Genomics Uppsala, Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden

3. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

4. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

5. Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

Funder

Akademiska Sjukhuset

Cancerfonden

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2021.1881161

Reference44 articles.

1. Population-based experience on primary central nervous system lymphoma 2000–2012: the incidence is increasing

2. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention

3. The blockade of immune checkpoints in cancer immunotherapy

4. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of coverage, generalisability and validity of the U‐CAN lymphoma biobank in Sweden: A comparison with nationwide registers;British Journal of Haematology;2024-09-03

2. The prognostic value of CD8 ⁺ CTLs, CD163 ⁺ TAMs, and PDL1 expression in the tumor microenvironment of primary central nervous system lymphoma;Leukemia & Lymphoma;2024-01-10

3. The role of comorbidity indices and histochemical markers in surgically resected and non-resected primary central nervous system lymphoma;Clinical and Experimental Medicine;2023-07-25

4. Interactions of IDO and the Kynurenine Pathway with Cell Transduction Systems and Metabolism at the Inflammation–Cancer Interface;Cancers;2023-05-24

5. Spatial single cell analysis of tumor microenvironment remodeling pattern in primary central nervous system lymphoma;Leukemia;2023-04-29